DreamCIS Selects Oracle Health Sciences Applications
Oracle Health Sciences applications has been chosen by DreamCIS, a contract research organization in Korea. DreamCIS required a clinical trial management system to replace its legacy clinical software solution and help enable the company’s biometrics center to become an Asian clinical trial data management hub.
DreamCIS intends to use Oracle Clinical and Oracle Remote Data Capture (RDC) 4.5.3 to help meet global standards for clinical trials data management and achieve higher quality local clinical trial services. DreamCIS is the first CRO in Korea to adopt the applications.
“Oracle’s proven experience in the health sciences sector was important to us and we believe their solutions will enable us to raise our data management levels to global standards, and help us become the leader in the Asian clinical trial markets in the future,” said Hee-Joong Koh, Director, Biometrics Center, DreamCIS.
Oracle RDC 4.5.3 uses the same data model as Oracle Clinical, ensuring tight integration of data between these applications. It is also completely Web-based, with a ‘zero client footprint’ for the HTML data entry window. This enables improved global access and performance for life sciences organizations to conduct global clinical studies more cost effectively whether using traditional pen and paper, electronic data capture, or hybrid methods.
“As the number of clinical trials increases in the Korean market and throughout Asia, there is a growing need for best-in-class software applications for clinical development and drug safety,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “We are committed to helping emerging CROs like DreamCIS accelerate insights for better health and look forward to supporting their efforts to become an important hub for clinical data management in the region.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Data Show Efficacy of Tezspire Treating Chronic Rhinosinusitis with Nasal Polyps
March 4th 2025Phase III WAYPOINT trial shows Tezspire (tezepelumab) significantly reduces nasal polyp size and congestion severity in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, while also decreasing the need for surgery and systemic glucocorticoids.
